Vaccination of non-allergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects and mechanisms

Publication date: Available online 22 November 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Raffaela Campana, Katharina Marth, Petra Zieglmayer, Milena Weber, Christian Lupinek, Yury Zhernov, Olga Elisyutina, Musa Khaitov, Eva Rigler, Kerstin Westritschnig, Uwe Berger, Martin Wolkersdorfer, Fritz Horak, Friedrich Horak, Rudolf Valenta

Summary

This is the first double-blind, placebo-controlled study showing that vaccination with recombinant hypoallergenic allergen-derivatives is safe and induces sustained allergen-specific IgG responses which block allergic patients IgE binding to the allergen.

https://ift.tt/2Ks2PXn